Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$258.00K$258.00K+41.0% vs Q2 2025 Net Income-$19.42M-$19.42MN/M vs Q2 2025 EPS Diluted-$0.54-$0.54N/M vs Q2 2025 Operating Income-$20,053,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-7772.5%+1.8 pt vs Q2 2025
Net margin-7526.0%−443.5 pt vs Q2 2025
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end